Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:MNPR Monopar Therapeutics (MNPR) Stock Price, News & Analysis $64.95 +9.75 (+17.66%) Closing price 04:00 PM EasternExtended Trading$64.00 -0.95 (-1.46%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Monopar Therapeutics Stock (NASDAQ:MNPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Monopar Therapeutics alerts:Sign Up Key Stats Today's Range$55.00▼$65.5550-Day Range$50.12▼$65.5252-Week Range$28.40▼$105.00Volume337,755 shsAverage Volume177,028 shsMarket Capitalization$435.17 millionP/E RatioN/ADividend YieldN/APrice Target$107.00Consensus RatingBuy Company Overview Monopar Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies. The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development. Monopar’s lead programs employ its PRIT platform to address both hematologic malignancies and solid tumors, and the company is also exploring antibody-drug conjugate approaches to expand its immunotherapeutic offerings. Through these efforts, Monopar seeks to deliver targeted, high-potency treatments that can overcome resistance and improve patient outcomes. Founded in 2018 and headquartered in Newton, Massachusetts, Monopar Therapeutics has established research collaborations and licensing agreements to advance its proprietary technologies. The company holds global rights to its PRIT platform, which was initially developed through academic partnerships, and maintains research operations in key U.S. life-science clusters. Monopar continues to strengthen its development capabilities through strategic collaborations with academic institutions and contract research organizations. Monopar is led by a management team with extensive experience in oncology drug development, radiopharmaceutical manufacturing and clinical operations. The leadership team combines scientific expertise and industry know-how to advance the company’s pipeline and navigate regulatory pathways. Together, they are working to bring next-generation targeted therapies to patients with high-need cancers.AI Generated. May Contain Errors. Read More Monopar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreMNPR MarketRank™: Monopar Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 515th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingMonopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMonopar Therapeutics has a consensus price target of $107.00, representing about 64.7% upside from its current price of $64.95.Amount of Analyst CoverageMonopar Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Monopar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Monopar Therapeutics are expected to decrease in the coming year, from ($3.03) to ($4.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monopar Therapeutics is -34.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monopar Therapeutics is -34.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonopar Therapeutics has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.37% of the float of Monopar Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonopar Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Monopar Therapeutics has recently decreased by 3.06%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonopar Therapeutics does not currently pay a dividend.Dividend GrowthMonopar Therapeutics does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.04 News SentimentMonopar Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Monopar Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Monopar Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.50% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.83% of the stock of Monopar Therapeutics is held by institutions.Read more about Monopar Therapeutics' insider trading history. Receive MNPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNPR Stock News HeadlinesMNPR stock rallies after hours as experimental drug shows rapid copper balance improvement in genetic disorderMay 19 at 11:44 PM | msn.comMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMay 19 at 5:33 PM | globenewswire.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 20 at 1:00 AM | Behind the Markets (Ad)HC Wainwright Analysts Increase Earnings Estimates for MNPRMay 18 at 2:31 AM | americanbankingnews.comMonopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson DiseaseMay 14, 2026 | quiverquant.comQMonopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 14, 2026 | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth PlansMay 4, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO)April 22, 2026 | theglobeandmail.comSee More Headlines MNPR Stock Analysis - Frequently Asked Questions How have MNPR shares performed this year? Monopar Therapeutics' stock was trading at $65.30 at the beginning of the year. Since then, MNPR stock has decreased by 0.5% and is now trading at $64.95. How were Monopar Therapeutics' earnings last quarter? Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.41. When did Monopar Therapeutics' stock split? Shares of Monopar Therapeutics reverse split before market open on Tuesday, August 13th 2024.The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. Does Monopar Therapeutics have any subsidiaries? Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL. When did Monopar Therapeutics IPO? Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager. Who are Monopar Therapeutics' major shareholders? Monopar Therapeutics' top institutional investors include Siren L.L.C. (4.03%), ADAR1 Capital Management LLC (3.94%), Bank of New York Mellon Corp (1.17%) and Walleye Capital LLC (0.94%). Insiders that own company stock include Tactic Pharma Llc, Chandler Robinson, Andrew Cittadine, Kim R Tsuchimoto, Christopher M Starr, Karthik Radhakrishnan and Quan Anh Vu. View institutional ownership trends. How do I buy shares of Monopar Therapeutics? Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monopar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Gold.com (GOLD), Tonix Pharmaceuticals (TNXP) and Viking Therapeutics (VKTX). Company Calendar Last Earnings5/14/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MNPR's financial health is in the Green zone, according to TradeSmith. MNPR has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MNPR CIK1645469 Webwww.monopartx.com Phone847-388-0349FaxN/AEmployees10Year Founded2014Price Target and Rating Average Price Target for Monopar Therapeutics$107.00 High Price Target$125.00 Low Price Target$74.00 Potential Upside/Downside+64.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-12.84% Return on Assets-12.57% Debt Debt-to-Equity RatioN/A Current Ratio56.04 Quick Ratio56.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.21 per share Price / Book3.21Miscellaneous Outstanding Shares6,700,000Free Float5,326,000Market Cap$435.17 million OptionableNot Optionable Beta1.49 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MNPR) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
